Incyte Corp
INCY
NASDAQ
Biotechnology
$120.16
USD
-0.36 (-0.30%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $24.41B
Volume 785.7K
Revenue
$5.82B
TTM
+26.9%
YoY
Gross Margin
93%
TTM
-0.3%
YoY
Net Income
$1.61B
TTM
+85.1%
YoY
Operating Cash Flow
$1.98B
TTM
+97.4%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 1,215.5 | 1,366.0 | 1,506.8 | 1,272.7 | 1,674.0 |
YoY Growth | +16.5% | +20.0% | +27.8% | +20.9% | +37.7% |
Cost of Revenue | 78.8 | 99.0 | 121.2 | 104.5 | 105.0 |
Gross Profit | 1,136.8 | 1,267.0 | 1,385.7 | 1,168.2 | 1,569.1 |
Selling, General & Administrative | 331.0 | 329.1 | 390.4 | 328.1 | 351.7 |
Other Operating Expenses | -219.5 | -12.2 | 48.0 | 23.0 | 2.5 |
Total Operating Expenses | 606.4 | 823.5 | 1,049.8 | 867.0 | 871.2 |
Operating Income | 530.3 | 443.5 | 335.9 | 301.1 | 697.9 |
EBITDA | 311.0 | 455.3 | 414.0 | 348.1 | 724.4 |
Other Income / Expense | 3.2 | 12.6 | 23.9 | 9.4 | 16.1 |
Total Other Income / Expense | 27.7 | 38.8 | 54.1 | 42.5 | 53.6 |
Income Before Income Taxes | 558.0 | 482.3 | 389.9 | 343.6 | 751.5 |
Income Taxes | 153.0 | 58.1 | 90.7 | 40.3 | 165.9 |
Net Income | 405.0 | 424.2 | 299.3 | 303.3 | 585.6 |
Consolidated Net Income / Loss | 405.0 | 424.2 | 299.3 | 303.3 | 585.6 |
Net Income Attributable to Common Shareholders | 405.0 | 424.2 | 299.3 | 303.3 | 585.6 |
Basic EPS | $2.09 | $2.17 | $1.52 | $1.52 | $2.92 |
Diluted EPS | $2.04 | $2.11 | $1.46 | $1.47 | $2.81 |
Basic Shares Outstanding | 194.0M | 195.7M | 197.4M | 199.3M | 200.4M |
Diluted Shares Outstanding | 198.7M | 201.4M | 204.4M | 206.8M | 208.2M |